NCT01479881View on ClinicalTrials.gov

A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Hepatitis C Virus
Interventions
DRUG

tacrolimus

a single 2-mg dose of tacrolimus (on Day 1 in treatment C and on Day 7 in treatment D).

DRUG

TMC435

TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).

DRUG

cyclosporine

A single 100-mg dose of cyclosporine (on Day 1 of treatment A and on Day 7 of treatment B).

DRUG

TMC435

TMC435, 150 mg daily for 10 days (Day 1 - 10 in treatment B).

Trial Locations (1)

Unknown

Merksem

All Listed Sponsors
lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY

NCT01479881 - A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus | Biotech Hunter | Biotech Hunter